Why the study?
Does idarucizumab reversal allow safe intravenous thrombolysis in patients with acute ischemic stroke on dabigatran?
Does idarucizumab reversal allow safe intravenous thrombolysis in patients with acute ischemic stroke on dabigatran?
Idarucizumab can safely reverse dabigatran to allow for acute stroke interventions like systemic thrombolysis.
May support emergency thrombolysis in dabigatran-treated stroke; leaves open need for prospective trials before practice change.
Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well-tolerated, and easy to manage in an emergency room or stroke unit.
No takes yet. Share an insight, caveat, or question.
Binet et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: